Nanordica Medical
Estonia - TallinnBiotechnology
Focus: Nanordica Medical is an Estonian biotechnology company focused on advanced wound care solutions, specifically antibacterial wound dressings for diabetic foot ulcers. Founded in 2023, the company is in early-stage development with minimal disclosed scale.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$1.75M
Open Jobs
0
About Nanordica Medical
AI assessmentNot HiringNo open roles listed right now. Follow Nanordica Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Advanced Antibacterial Wound Dressing
Diabetic Foot UlcerClinical Trials (1)
NCT06667752Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer
N/AHelp build intelligence for Nanordica Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.